Update on CHAMPION, Phase 3 clinical trial of ION582 (obudanersen)
Ionis shares an update on CHAMPION, its Phase 3 trial for ION582 (obudanersen) in Angelman syndrome due to UPD or ICD, with eligibility details now on clinicaltrials.gov.
Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial
Oak Hill Bio shares a community letter marking the first participant dosed in its BEACON study, thanking families and investigators for making this milestone possible.
An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials
Ionis shares an update on ION582 development, covering progress across the HALOS, REVEAL, and newly announced CHAMPION trials expanding research into additional AS genotypes.
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Ionis Pharmaceuticals has dosed the first participant in its global Phase 3 REVEAL trial, evaluating the safety and efficacy of ION582 as a potential treatment for Angelman syndrome.